Recombinant human growth hormone therapy for childhood trichorhinophalangeal syndrome type i: a case report

HIGHLIGHTS

• who: Dan Huang and colleagues from the Department of Child Health Care, Women`s (Hangzhou Maternity and Child Care, China Department of Endocrinology, The Children`s, Zhejiang University School of Medicine have published the research work: Recombinant Human Growth Hormone Therapy for Childhood Trichorhinophalangeal Syndrome Type I: A Case Report, in the Journal: Children 2022, 1447 of /2022/
• what: The authors report an 11-year-old Chinese boy with TRPS I with the typical clinical manifestations and a likely novel pathogenic nonsense variant in exon 4 of TPRS1, who had an excellent growth response to . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.